Industry
Industry in One Page
US for-profit hospital operators sell hospital and outpatient procedures to a small number of large payers — Medicare, state Medicaid programs, and a handful of commercial insurers — in regulated local markets where prices are negotiated, not posted. Acute and surgical care is fixed-cost with high operating leverage: when revenue per case beats wage growth, margins expand sharply; when it doesn't, they collapse. Three forces dominate the cycle today — the migration of surgery from hospitals into ambulatory surgery centers (ASCs), the expiry of enhanced Affordable Care Act exchange subsidies (EPTCs) at year-end 2025, and the One Big Beautiful Bill Act (OBBBA) signed July 2025 which tightens Medicaid eligibility and supplemental payments from 2027. Newcomers most often misread this as a "growth" industry. It isn't. Same-hospital admissions barely move year-to-year (THC Q4 2025: total admissions +0.4% YoY, utilization 49.8%); economic value is created by acuity mix, payer mix, and site shift to lower-cost outpatient settings — not by volume.
Takeaway: Hospital operators are price-takers from government programs and commercial insurers, and price-givers to fragmented physician and labor markets. Profit lives in the spread between negotiated payer rates and labor+supply cost per case — and in shifting cases to ASCs where that spread is structurally wider.
How This Industry Makes Money
Hospital operators bill per case — a discharge, a surgery, an emergency-department visit, an outpatient procedure — at heavily negotiated rates. Medicare pays via fixed Diagnosis-Related Group (DRG) prices set by CMS each year. Medicaid pays state-set rates topped up by supplemental payments (provider-tax and state-directed payment programs that recycle hospital fees back as enhanced reimbursement). Commercial managed-care payers — the source of ~70% of Tenet's hospital revenue — negotiate multi-year contracts with annual escalators of 3–5%. The economics break into a hospital business and an ambulatory business with different unit economics.
Where the bargaining power sits: with commercial payers (rate negotiations and narrow networks), physicians (they choose where to admit and which ASCs to invest in), and government (CMS rules and Medicaid supplemental payment rules can move multi-billion-dollar profit pools with one regulation). Hospitals get scale leverage on supplies and admin, but almost none on labor — wages are set by local market, union contracts (20% of THC hospital workforce), and state laws like California's healthcare-worker minimum wage (effective October 2024 with annual escalators through 2028).
Takeaway: Hospital revenue is almost entirely a function of (case volume × payer mix × case acuity × negotiated rate) minus a labor cost stack that grows whether or not volume does. ASCs change the math by stripping out hospital overhead and rising acuity — which is why every for-profit operator is rotating capital toward ambulatory.
Demand, Supply, and the Cycle
Underlying demand is demographic and durable — the 65+ population is growing, chronic-disease prevalence is rising, and procedures-per-capita inch up each decade. Aggregate hospital admission demand is essentially flat: US hospital occupancy hovers in the high 60s%, and Tenet's Q4 2025 licensed-bed utilization was 49.8% (down 70 bps YoY). The cycle is not industrial — it is a policy and payer cycle.
Two recent cycles bracket today's expectations: the 2020–2022 pandemic cycle (volume crash, then volume recovery + acute labor inflation that inverted hospital margins for many operators) and the 2014–2018 ACA expansion cycle (Medicaid expansion reduced uninsured admissions in expansion states, lifting margin in expansion-state operators). Tenet sits more heavily in non-expansion states — over half of licensed beds in Florida, South Carolina, Tennessee, and Texas — making its hospital segment more sensitive to commercial coverage and exchange enrollment than peers concentrated in expansion states.
Cycle position now (May 2026): The industry is in the early phase of a payer-mix downturn: enhanced ACA exchange subsidies expired 12/31/2025, premiums are spiking, exchange enrollment is falling, and management teams across HCA, THC, UHS are now guiding to declining "exchange admissions" through 2026. The bigger shoe — OBBBA's 2027 Medicaid changes — has not yet hit reported numbers.
Competitive Structure
The US hospital market is locally concentrated, nationally fragmented, and bifurcated by ownership form. The five largest for-profit chains (HCA, Tenet, CHS, UHS, Encompass) together operate roughly 500–600 of the country's ~5,500 community hospitals; the rest are non-profit health systems (CommonSpirit, Ascension, AdventHealth, Kaiser), academic medical centers, public hospitals, and independents. For-profits compete with each other on capital allocation and ambulatory strategy, and with non-profits on labor and managed-care contracts in shared local markets. Non-profits are exempt from federal income tax, state property tax, and have access to tax-exempt bond financing — a structural cost-of-capital edge.
Two structural notes worth internalizing. First, ASCs are a different competitive game from hospitals: typically joint ventures with the physicians who use them, which makes physician syndication (not patient acquisition) the binding growth constraint. Second, the non-profit overhang matters more than it looks — non-profits' tax exemption is worth ~200–400 bps of after-tax margin, which is why for-profits compete by scaling administrative functions (revenue cycle, supply chain) and rotating capital into ASCs where non-profits have weaker physician relationships.
Takeaway: This is not a winner-take-all industry. It is a "win locally, scale ambulatory" industry. National brand barely matters; market share in San Antonio, Phoenix, and El Paso (Tenet's largest hospital markets) and physician relationships in 37 states (USPI footprint) are what drive returns.
Regulation, Technology, and Rules of the Game
This is the most regulated industry on the S&P 500 outside utilities and banks. Every revenue dollar passes through CMS rules, state Medicaid agencies, accreditation requirements, antifraud statutes, and HIPAA. Three regulatory threads dominate the 2026 investor view.
Two regulatory dates to remember: Jan 1, 2026 — EPTC subsidy expiration begins biting exchange enrollment. Jan 1, 2027 — OBBBA Medicaid provisions and the rescheduled Medicaid DSH cut begin to flow through. Most sell-side and management commentary frames FY2026 as a "navigate exchange headwinds" year and FY2027 as the bigger Medicaid risk year.
The Metrics Professionals Watch
Forget generic ratios. The eight metrics below are what hospital and ASC analysts use, and they appear in every quarterly disclosure for THC, HCA, UHS, CYH, SGRY, and ACHC.
Takeaway: The single most predictive number in any hospital quarter is same-hospital revenue per adjusted admission, because it captures both pricing and acuity in one line. The single most predictive ASC number is same-facility revenue growth. Watch those two before any reported earnings figure.
Where Tenet Healthcare Corporation Fits
Tenet is the only US listed for-profit hospital operator with a scaled ambulatory surgery platform — its defining characteristic. The Hospital Operations segment (50 acute hospitals + 132 outpatient sites + Conifer revenue cycle) places Tenet in the second-tier scale group with UHS and CYH, well behind HCA. The Ambulatory Care segment (USPI: 533 ASCs + 26 surgical hospitals across 37 states) makes Tenet a hybrid of HCA-style hospital operator and Surgery Partners-style ambulatory pure-play, on top of the largest national ASC platform.
Chart note: Tenet EV/EBITDA estimate uses FY2025 GAAP operating income + D&A as the EBITDA proxy ($4.1B); ACHC excluded — TTM EBITDA was negative due to FY2025 impairments. Adjusted-EBITDA multiples (used by management and most sell-side) print lower; HCA, THC and SGRY would all compress on that basis.
Takeaway: In an industry where most operators are hospital-only, Tenet's ASC platform is the single biggest differentiator and the reason its consolidated growth and margin profile look better than UHS or CYH despite a smaller hospital footprint. The investment debate is whether USPI's ambulatory profit pool can grow fast enough to outweigh OBBBA-era Medicaid headwinds in the hospital segment.
What to Watch First
Signals that tell whether the industry backdrop is helping or hurting Tenet:
Bottom line for the rest of this report: Read every section that follows through two lenses — (1) what is happening to the payer mix and revenue per case, which sets near-term hospital margin, and (2) what is happening to USPI's same-facility growth and ASC acquisition pace, which sets the medium-term growth and margin trajectory. The OBBBA-driven 2027 Medicaid risk is the single biggest macro variable that could overwhelm both.